Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 10/20 | 0.56 |
| ▸ | TDO2 | P48775 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2983658 | 0.84 | IDO1 (0.61) | IDO1TDO2MAPTKDM4EGAA | |
| SCHEMBL20340898 | 0.81 | IDO1 (0.67) | IDO1TDO2MAPTKDM4EGAA | |
| SCHEMBL19273916 | 0.80 | IDO1 (0.77) | IDO1TDO2MAPTKDM4EGAA | |
| SCHEMBL25458052 | 0.80 | IDO1 (0.52) | IDO1TDO2MAPTKDM4EGAA | |
| SCHEMBL15628059 | 0.80 | IDO1 (0.69) | IDO1TDO2MAPTKDM4EGAA | |
| SCHEMBL25471034 | 0.79 | IDO1 (0.67) | IDO1TDO2MAPTKDM4EGAA | |
| SCHEMBL25471276 | 0.79 | IDO1 (0.67) | IDO1TDO2MAPTKDM4EGAA | |
| SCHEMBL25762243 | 0.78 | IDO1 (0.70) | IDO1TDO2MAPTKDM4EGAA | |
| SCHEMBL21686849 | 0.78 | IDO1 (0.58) | IDO1TDO2MAPTKDM4EGAA | |
| SCHEMBL25762241 | 0.77 | IDO1 (0.72) | IDO1TDO2MAPTKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011643-B2 | Freeze-dried preparation containing high-purity PTH and method for producing same | ASAHI KASEI PHARMA CORPORATION (JP) | 2018-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011643-B2 | Freeze-dried preparation containing high-purity PTH and method for producing same | PTH1R, PTMS, VIP | IDO1 4715/4885TDO2 4359/4885MAPT 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.